| Nov 13 |
Tenax Therapeutics GAAP EPS of -$0.19
|
| Nov 13 |
Tenax Therapeutics: Q3 Earnings Snapshot
|
| Nov 13 |
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
|
| Oct 31 |
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
|
| Aug 22 |
TENX: $100 Million Capital Raise
|
| Aug 13 |
Tenax Therapeutics GAAP EPS of -$1.83 beats by $0.42
|
| Aug 13 |
Tenax Therapeutics: Q2 Earnings Snapshot
|
| Aug 13 |
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
|
| Aug 12 |
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
|
| Aug 6 |
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
|
